Name of the issue: Manipal Health Enterprises Limited

1 **Type of issue (IPO/ FPO)** IPO

2 **Issue size (Rs. in crore)** 9,275.22

3 **Grade of issue alongwith name of the rating agency**
Name
Grade
Not Applicable

4 **Subscription Level (Number of times)** [(1)] 3.28
Source: Basis of Allotment Ad dated August 4, 2026
(1) Figure is after technical rejections

5 **QIB holding (as a %age of total outstanding capital) as disclosed to stock exchanges**

Particulars	%
(i) On Allotment August 3, 2026	9.11%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (Sep 30, 2026)*	N.A.
(iii) at the end of 1st FY (March 31, 2027)*	N.A.
(iv) at the end of 2nd FY (March 31, 2028)*	N.A.
(v) at the end of 3rd FY (March 31, 2029)*	N.A.

**will be updated in due course*

6 **Financials of the issuer (consolidated basis)** *(Rs. Million)*

Parameters	31-Mar-27	31-Mar-28	31-Mar-29
Revenue from operations	Not Available	Not Available	Not Available
Net Profit for the period	Not Available	Not Available	Not Available
Paid up equity share capital	Not Available	Not Available	Not Available
Other Equity	Not Available	Not Available	Not Available

Note: Financials for the year ended March 31, 2027, March 31, 2028 and March 31, 2029 shall be updated in due course

7 **Trading status in the scrip of the issuer**

Company's Equity Shares are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE")

Particulars	Status
(i) at the end of 1st FY (March 31, 2027)[(1)]	Not Available
(ii) at the end of 2nd FY (March 31, 2028) [(1)]	Not Available
(iii) at the end of 3rd FY (March 31, 2029) [(1)]	Not Available

(1) will be updated in due course

All the above information is updated till August 15, 2026 unless indicated otherwise

8 **Change, if any, in directors of issuer from the disclosures in the offer document**

Particulars	Name of Director	Appointed / Resigned
During year ended March 31, 2027[1]	Not Available	
During year ended March 31, 2028[1]	Not Available	
During year ended March 31, 2029[1]	Not Available	

(1) Change in Directors of Issuer is not updated as the relevant financial years have not been completed

9 **Status of implementation of project/ commencement of commercial production**

Particulars	Remarks
(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

10 **Status of utilization of issue proceeds**

(i) as disclosed in the offer document

Rs. in Million

Particulars	Amount which will be financed from Net Proceeds	Estimated Utilisation of Net Proceeds		
		FY 2027	FY 2028	FY 2029
Repayment/ prepayment, in full or in part, of certain outstanding borrowings and accrued interest thereon availed by one of our Material Subsidiaries, Manipal Hospitals Private Limited	55,527.59	55,527.59	0	0
Acquisition of minority stake in our stepdown Subsidiary, Sahyadri Hospitals Private Limited	5,740.00	5,740.00	0	0
General corporate purposes	16,289.28	4,886.78	4,886.78	6,515.72
Total	**77,556.87**	**66,154.37**	**4,886.78**	**6,515.72**

(ii) Actual utilization	Nil
(iii) Reasons for deviation, if any	None

11 **Comments of monitoring agency, if applicable**

(i) Comments on use of funds	None
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	None
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	None

12 **Price-related data**

Designated SE	NSE
Issue Price (Rs.)	590
Listing Date	August 5, 2026

Price parameters	At close of listing day August 5, 2026	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of March 31, 2027		
				Closing price during FY	High during FY	Low during FY
Market Price	666.95	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty 50	24,624.65	Not Available	Not Available	Not Available	Not Available	Not Available

Price parameters	As at the end of March 31, 2028			As at the end of March 31, 2029		
	Closing price during FY	High during FY	Low during FY	Closing price during FY	High during FY	Low during FY
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty 50	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

Source: Stock Exchange data. Where the 30th day / 90th day/ March 31 of a particular year falls on a holiday, the immediately preceeding trading day has been considered

13 **Basis for Issue Price and Comparison with Peer Group & Industry Average**

Accounting ratio	Name of company	Face Value (Rs.)	As disclosed in the offer document	At the end of 1st FY March 31, 2027**	At the end of 2nd FY March 31, 2028**	At the end of 3rd FY March 31, 2029**
EPS	**Issuer: Consolidated** (1)	2	7.67	-	-	-
	Peer Group:					
	Apollo Hospitals Enterprise Ltd	5	135.04			
	Fortis Healthcare Ltd	10	13.8			
	Max Healthcare Institute Ltd	10	14.83			
	Industry Avg		54.56			
P/E	**Issuer: Consolidated**	2	76.92	-	-	-
	Peer Group:					
	Apollo Hospitals Enterprise Ltd	5	66.15			
	Fortis Healthcare Ltd	10	70.22			
	Max Healthcare Institute Ltd	10	74.55			
	Industry Avg		70.31			
RoNW%	**Issuer: Consolidated** (3)	2	10.57%	-	-	-
	Peer Group:					
	Apollo Hospitals Enterprise Ltd	5	NA			
	Fortis Healthcare Ltd	10	NA			
	Max Healthcare Institute Ltd	10	NA			
	Industry Avg:		NA			
NAV per share	**Issuer: Consolidated** (4)	2	72.55	-	-	-
	Peer Group:					
	Apollo Hospitals Enterprise Ltd	5	NA			
	Fortis Healthcare Ltd	10	NA			
	Max Healthcare Institute Ltd	10	NA			
	Industry Avg:		NA			

All the financial information for listed industry peers mentioned above is on a consolidated basis and is sourced from the financial results of the respective company for the year ended March 31, 2026 submitted to stock exchanges

Data not reported by Listed Peers in its audited consolidated financial statement, annual report, investor presentation or website and hence has been mentioned as 'NA' i.e. Not Available.

Price/earnings ratio of our Company has been computed based on the Offer Price divided by the diluted earnings per share for financial year ended March 31, 2026.

Price/earnings ratio for the peers has been computed based on the closing market price of equity shares on NSE as on July 21, 2026 divided by the diluted earnings per share for financial year ended March 31, 2026.

Net Asset Value per share is calculated as net worth at the end of the year divided by number of equity shares outstanding at the end of the year. Number of equity shares outstanding at the end of the year is an aggregate of outstanding number of equity shares considering dilutive number of shares.

Return on Net Worth is calculated as Profit/(loss) for the year attributable to owners of the Company divided by Net Worth as of at the end of the respective year.
Net Worth has been defined as the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of restated consolidated statement of profit and loss, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the restated consolidated statement of assets and liabilities, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation. Further, Net Worth is calculated as the sum of equity share capital, other equity, foreign currency translation reserve, and adjustments for re-measurement of the defined benefit plan.

***Not available as the relevant fiscal year has not been completed / information not disclosed*

14 **Any other material information**

Particulars	Date
Nil	Nil
For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com	